The iwNHL 2023 agenda will be available soon.
iwNHL 2022 agenda
Friday: September 9, 2022
6:30pm-8:00pm
Welcome Reception
Saturday: September 10, 2022
8:00am-8:10am
Introduction and Meeting Objectives
John Gribben
8:10am-9:50am
Session 1: T-cell lymphoma
Chairs: Laurence de Leval & Francine Foss
- Intestinal T-cell lymphoproliferative disorders; Laurence de Leval
- Experience with the management of enteropathy-associated
T-cell lymphomas and refractory celiac disease; David Sibon - Genetics and epigenetics of T-PLL; Reiner Siebert
- AUTO4 CAR-T in T-cell lymphoma; Kate Cwynarski
- Epigenetic drugs in T-cell lymphoma; François Lemonnier
- What is new in the treatment of cutaneous T-cell lymphomas; Steven Horwitz
Panel Discussion
9:50am-10:10am
Break
10:10am-11:45am
Session 2: Immunotherapy of lymphoma
Chairs: Stephen Ansell & John Gribben
Overview lecture: Engaging the innate & adaptive antitumor immune response in lymphoma; Stephen Ansell
- CAR-T and the tumor microenvironment – DLBCL as a model; John Kuruvilla
- IMiDs in combination; Francisco Hernandez-Ilizaliturri
- Checkpoint inhibitors; Gaël Roué
- Salvage and bridging treatments in R/R LBCL; Georg Lenz
- Double-hit lymphoma – optimizing therapy; Kieron Dunleavy
Panel Discussion
11:45am-12:30pm
Session 3: Keynote address – Mantle cell lymphoma; Elias Campo
Chair & Introduction; Reiner Siebert
Panel Discussion
12:30pm-1:30pm
Lunch
1:30pm-2:50pm
Session 4: Management of follicular lymphoma beyond first-line therapy
Chairs: Laura Pasqualucci & Jessica Okosun
- Epigenetic alterations in the development of FL; Jessica Okosun
- Transformed FL treatment options; Anna Sureda
- Prognostic factors in patients with relapsed or refractory disease; Laura Pasqualucci
- Mechanisms of action and opportunities for synergy in FL-directed therapies; David Qualls
- How do I sequence therapy for follicular lymphoma? Gilles Salles
Panel Discussion
2:50pm-4:20pm
Session 5: T-cell therapies for lymphoma
Chairs: Catherine Bollard & David Maloney
- CD19-CAR-T – real-world experience (commercial CARs); Jeremy Abramson
- CD19-CAR-T – next-generation CD19-CAR-T (Humanized CARs, allo ‘off-the-shelf” CARs etc); David Maloney
- CD20-CAR-T; Mazyar Shadman
- CD30 CAR-T; Barbara Savoldo
- CAR-T for T-cell lymphoid malignancies – using T-ALL as an example; Maksim Mamonkin
- Third party EBV T-cells for EBV lymphomas; Catherine Bollard
Panel Discussion
4:20pm-4:40pm
Break
4:40pm-5:50pm
Session 6: Novel therapies part 1
Chairs: Laurie Sehn & Jason Westin
ADCs:
- POLARIX – Polatuzumab vedotin; Laurie Sehn
- Loncastuximab Tesirine; Carmelo Carlo-Stella
- ADCT–301 – Camidanlumab tesirine; Graham Collins
- Brentuximab vedotin; David Straus
Panel Discussion
5:50pm-6:00pm
Day 1 wrap-up and close
7:00pm
Faculty Dinner
Sunday: September 11, 2022
7:30am-8:30am
Breakfast
8:30am-9:50am
Session 6: Novel therapies part 2
Chairs: Marion Subklewe & Carmelo Carlo-Stella
CD20/CD3 bispecific antibodies: How to choose?
- Redirecting T-cell activity with Anti-BCMA/Anti-CD3 bispecific antibodies in CLL; Arnon Kater
- Mosunetuzumab; Loretta Nastoupil
- Odronextamab (REGN1979); Rajat Bannerji
- DuoBody-CD3xCD20 (Epcoritamab); Stephen Schuster
Panel Discussion
9:50am-10:10am
Break
10:10am-11:30am
Session 7: BTK inhibitors
Chairs: Loretta Nastoupil & Marek Trněný
Established and novel BTK inhibitors: how to choose?
- Ibrutinib combinations; Loretta Nastoupil
- Zanubrutinib; Alessandra Tedeschi
- Acalabrutinib; Marek Trněný
- Pirtobrutinib (LOXO-305); Anthony Mato
Panel Discussion
11:30am-12:20pm
Session 8: Point/counterpoint – BiTEs versus CARs for NHL
Chairs: Catherine Bollard & David Maloney
- Point: CAR-T for NHL; Jason Westin
- Counterpoint: BiTEs for NHL; Marion Subklewe
Panel Discussion
12:20pm-12:30pm
Final Meeting Summary & Conclusions
iwNHL Committee
12:30pm
Lunch